Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CLDINASDAQ:INABNASDAQ:PALINASDAQ:SYBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDICalidi Biotherapeutics$0.46+10.6%$0.58$0.35▼$4.90$13.06M1.21878,432 shs114,206 shsINABIN8bio$0.16-6.3%$0.19$0.13▼$1.74$14.29M0.231.88 million shs494,977 shsPALIPalisade Bio$0.73-5.2%$0.76$0.60▼$6.71$3.32M1.46493,122 shs23,595 shsSYBXSynlogic$1.12-5.1%$1.17$0.90▼$1.88$13.10M0.5619,398 shs7,018 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDICalidi Biotherapeutics0.00%-7.87%+12.48%-64.70%+45,889,900.00%INABIN8bio0.00%-7.14%+7.00%-39.46%-84.42%PALIPalisade Bio0.00%-8.44%+7.01%-41.96%-89.72%SYBXSynlogic0.00%-3.45%+5.66%-14.83%-40.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDICalidi Biotherapeutics1.4148 of 5 stars3.50.00.00.00.01.70.6INABIN8bio3.5481 of 5 stars3.55.00.00.02.52.51.3PALIPalisade Bio2.9697 of 5 stars3.55.00.00.02.60.01.3SYBXSynlogic2.1771 of 5 stars0.05.00.00.03.31.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDICalidi Biotherapeutics 3.00Buy$15.003,168.69% UpsideINABIN8bio 3.00Buy$6.003,711.94% UpsidePALIPalisade Bio 3.00Buy$23.003,070.23% UpsideSYBXSynlogic 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PALI, INAB, SYBX, and CLDI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/14/2025INABIN8bioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $6.002/12/2025INABIN8bioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 5/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDICalidi Biotherapeutics$50K261.28N/AN/A($2.32) per share-0.20INABIN8bioN/AN/AN/AN/A$0.58 per shareN/APALIPalisade Bio$250K12.76N/AN/A$18.29 per share0.04SYBXSynlogic$8K1,637.44N/AN/A$4.64 per share0.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDICalidi Biotherapeutics-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/AINABIN8bio-$30.01M-$0.45N/AN/AN/AN/A-197.15%-130.48%N/APALIPalisade Bio-$12.30M-$10.92N/AN/AN/AN/A-148.51%-115.16%5/12/2025 (Estimated)SYBXSynlogic-$57.28M-$2.51N/AN/AN/AN/A-207.84%-114.81%5/13/2025 (Estimated)Latest PALI, INAB, SYBX, and CLDI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SYBXSynlogic-$0.15N/AN/AN/AN/AN/A5/12/2025Q1 2025PALIPalisade Bio-$0.84N/AN/AN/AN/AN/A5/8/2025Q1 2025INABIN8bio-$0.06-$0.07-$0.01-$0.07N/AN/A3/24/2025Q4 2024PALIPalisade Bio-$2.39-$0.69+$1.70-$0.69N/AN/A3/13/2025Q4 2024INABIN8bio-$0.07-$0.04+$0.03-$0.04N/AN/A3/6/2025Q4 2024SYBXSynlogic-$0.10-$0.06+$0.04-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDICalidi BiotherapeuticsN/AN/AN/AN/AN/AINABIN8bioN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ASYBXSynlogicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDICalidi BiotherapeuticsN/A0.190.19INABIN8bio0.051.841.84PALIPalisade BioN/A3.313.31SYBXSynlogicN/A2.712.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDICalidi Biotherapeutics12.53%INABIN8bio92.05%PALIPalisade Bio11.79%SYBXSynlogic63.40%Insider OwnershipCompanyInsider OwnershipCLDICalidi Biotherapeutics24.28%INABIN8bio15.50%PALIPalisade Bio3.28%SYBXSynlogic3.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDICalidi Biotherapeutics3828.47 million20.04 millionN/AINABIN8bio2090.77 million61.25 millionNot OptionablePALIPalisade Bio104.40 million2.68 millionNot OptionableSYBXSynlogic8011.70 million11.34 millionOptionablePALI, INAB, SYBX, and CLDI HeadlinesRecent News About These CompaniesSynlogic's executive sells shares worth $2,802February 5, 2025 | msn.comSynlogic Reports Q3 2024 Financial OutcomesNovember 14, 2024 | markets.businessinsider.comSynlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deSynlogic Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | globenewswire.comSynlogic preps phenylketonuria drug for phase 3 after mid-stage winNovember 6, 2024 | pharmaphorum.comSynlogic, Inc. (0A8U.L)August 24, 2024 | nz.finance.yahoo.comMIN.SG,0P0001I7V6,0 (MIN.SG)August 16, 2024 | nz.finance.yahoo.comMaintaining Hold on Synlogic Amid Strategic Reassessment and Financial UncertaintyAugust 14, 2024 | markets.businessinsider.comSynlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | finanznachrichten.deSYBX Stock Earnings: Synlogic Beats EPS for Q2 2024August 8, 2024 | investorplace.comSynlogic Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comSynlogic Inc.July 21, 2024 | wsj.comSynlogic Inc SYBXJuly 21, 2024 | morningstar.comThe Summer Stock Exodus: 3 Companies to Ditch Before the Heat HitsMay 23, 2024 | investorplace.comHold Rating Maintained for Synlogic Amidst Setbacks and Financial UncertaintiesMay 16, 2024 | markets.businessinsider.comSYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | investorplace.comSynlogic, Inc.: Synlogic Reports First Quarter 2024 Financial ResultsMay 14, 2024 | finanznachrichten.deSynlogic Flat on Q1 NumbersMay 14, 2024 | baystreet.caSynlogic Reports First Quarter 2024 Financial ResultsMay 14, 2024 | globenewswire.comWe Think Synlogic (NASDAQ:SYBX) Needs To Drive Business Growth CarefullyMay 9, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit3 High-Yield Dividend Stocks Trading at a DiscountBy Nathan Reiff | April 14, 2025View 3 High-Yield Dividend Stocks Trading at a DiscountDisney Stock Jumps on Earnings—Is the Magic Sustainable?By Chris Markoch | May 7, 2025View Disney Stock Jumps on Earnings—Is the Magic Sustainable?PALI, INAB, SYBX, and CLDI Company DescriptionsCalidi Biotherapeutics NYSE:CLDI$0.46 +0.04 (+10.58%) As of 05/9/2025 04:00 PM EasternCalidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.IN8bio NASDAQ:INAB$0.16 -0.01 (-6.25%) As of 05/9/2025 04:00 PM EasternIN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.Palisade Bio NASDAQ:PALI$0.73 -0.04 (-5.15%) As of 05/9/2025 03:30 PM EasternPalisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.Synlogic NASDAQ:SYBX$1.12 -0.06 (-5.08%) As of 05/9/2025 03:59 PM EasternSynlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock Constellation Powers Up With Reinforced AI Data Center Strategy GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
